Seagen, astellas and merck announce results of clinical trial investigating padcev® (enfortumab vedotin-ejfv) with keytruda® (pembrolizumab) and padcev as monotherapy in first-line advanced urothelial cancer

Bothell, wash. & tokyo & rahway, n.j.--(business wire)--seagen inc. (nasdaq:sgen), astellas pharma inc. (tse:4503, president and ceo: kenji yasukawa, ph.d., “astellas”) and merck (nyse: mrk), known as msd outside of the united states and canada, today announced results from the phase 1b/2 ev-103 clinical trial (also known as keynote-869) cohort k investigating padcev® (enfortumab vedotin-ejfv) in combination with merck's anti-pd-1 therapy keytruda® (pembrolizumab) and padcev alone as first-line
SGEN Ratings Summary
SGEN Quant Ranking